文献速递心脑血管急症复苏、休克与脓毒症

利多卡因与胺碘酮治疗成人院内难治性室颤/无脉性室速的比较效果:来自中国全国多中心注册登记研究的见解

Comparative Effectiveness of Lidocaine and Amiodarone for Refractory Ventricular Fibrillation/Pulseless Ventricular Tachycardia in Adult In-Hospital Cardiac Arrest: Insights From a Nationwide Multicenter Chinese Registry.
PubMed 文献 · Chest · 2026-09-21
一句话结论在成人院内难治性室颤/无脉性室速中,利多卡因与胺碘酮在生存率或神经功能结局方面无显著差异,支持指南允许使用任一抗心律失常药物的推荐。

该研究基于中国40家医院参与的前瞻性多中心院内心脏骤停注册登记数据,纳入2019年7月至2020年12月期间接受利多卡因或胺碘酮治疗的成人院内难治性室颤/无脉性室速患者612例(利多卡因259例,胺碘酮353例)。主要终点为出院或30天生存率,次要终点为持续自主循环恢复和出院或30天良好神经功能结局(CPC 1/2)。未调整和 multivariable 调整后分析均显示两组在生存率、持续ROSC和神经功能结局方面无显著差异。研究结果为指南允许在复苏期间使用任一抗心律失常药物提供了真实世界证据支持。

要点

  • 该研究为基于全国多中心前瞻性注册登记的真实世界证据,支持指南允许在复苏期间使用任一抗心律失常药物的推荐。

适用人群与场景

  • 成人(年龄未在原文具体说明)院内心脏骤停患者,表现为难治性室颤或无脉性室速,且接受了利多卡因或胺碘酮治疗。
  • 数据来源于中国40家医院参与的前瞻性多中心院内心脏骤停注册登记(Baseline Investigation of In-Hospital Cardiac Arrest Registry),收集Utstein风格数据。
  • 纳入时间为2019年7月至2020年12月;所有合格病例均通过病历审查进行裁定,以确保严格遵循指南推荐的药物使用指征。

诊断标准与关键阈值

  • 难治性室颤/无脉性室速的定义及具体标准原文未提及。
  • 良好神经功能结局定义为出院或30天时脑功能分类(CPC)1或2。
  • 主要终点为出院或30天生存;次要终点为持续自主循环恢复(ROSC)和出院或30天良好神经功能结局。

处置流程与药物剂量

  • 原文未提及利多卡因或胺碘酮的具体剂量、给药途径、频次或疗程。
  • 原文仅说明纳入患者接受了利多卡因或胺碘酮治疗,且病例经裁定以确保严格遵循指南推荐的药物使用指征。

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 研究类型:基于全国多中心前瞻性注册登记(40家医院)的队列数据分析;样本量:从32,545例成人院内心脏骤停中筛选出612例符合条件者(利多卡因n=259,胺碘酮n=353)。
  • 预设亚组分析结果一致(原文未提供亚组具体数值)。
  • 不良事件:原文未提及。

证据类型、等级与局限

  • 证据类型:基于全国多中心前瞻性注册登记的观察性队列研究(非随机对照试验)。
  • 证据等级或推荐强度:原文未提及。
  • 局限:原文未明确列出局限性;设计本身为观察性研究,存在混杂可能性,尽管采用了多变量调整和预设亚组分析。

对床旁实践的改变

  • 对于成人院内难治性室颤/无脉性室速,利多卡因与胺碘酮在生存率、持续ROSC和神经功能结局方面无显著差异,支持指南允许使用任一药物。
  • 该结论基于经严格裁定的全国多中心前瞻性注册登记真实世界数据,适用于成人院内心脏骤停场景。
  • 原文未提及具体的适用或不适用人群排除标准,临床决策仍需结合患者具体情况和指南。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

BACKGROUND: Current resuscitation guidelines recommend either amiodarone or lidocaine for refractory ventricular fibrillation (VF) or pulseless ventricular tachycardia (pVT), primarily based on out-of-hospital cardiac arrest evidence. Whether the 2 agents differ in effectiveness for adult in-hospital cardiac arrest (IHCA) with refractory VF/pVT remains uncertain.

RESEARCH QUESTION: Among adult patients with IHCA with refractory VF/pVT, does lidocaine differ from amiodarone in survival or neurologic outcomes?

STUDY DESIGN AND METHODS: We conducted data analysis based on data from the nationwide, multicenter, prospective Baseline Investigation of In-Hospital Cardiac Arrest Registry, which collects Utstein-style IHCA data from 40 hospitals across China. We included adults with refractory VF/pVT who received lidocaine or amiodarone between July 2019 and December 2020. All eligible cases were carefully adjudicated by reviewing medical records to ensure strict adherence to the recommended indications for medication in the guidelines. The primary outcome was survival to hospital discharge or 30 days; secondary outcomes were sustained return of spontaneous circulation (ROSC) and favorable neurologic outcome at discharge or 30 days (CPC 1/2). Associations were evaluated using multilevel mixed-effects logistic regression with prespecified subgroup analyses.

RESULTS: Of 32,545 adult IHCA cases, 612 met inclusion criteria (lidocaine: n = 259; amiodarone: n = 353). Unadjusted outcomes were similar between groups: survival (20.1% vs 23.5%; P = .31), sustained ROSC (47.9% vs 51.6%; P = .38), and favorable neurologic status (17.0% vs 21.0%; P = .22). After multivariable adjustment, no significant differences were observed for survival (adjusted OR, 1.22; 95% CI, 0.63-2.37; P = .55), sustained ROSC (adjusted OR, 1.21; 95% CI, 0.77-1.91; P = .40), or neurologic outcome (adjusted OR, 1.44; 95% CI, 0.70-2.99; P = .32), with consistent exploratory subgroup findings.

INTERPRETATION: To our knowledge, this is the first study to compare lidocaine and amiodarone specifically in a rigorously adjudicated cohort of adult patients with refractory VF/pVT IHCA from a national, multicenter, prospective registry. Our results show that there were no significant differences in outcomes between the 2 agents, providing real-world evidence that supports guideline recommendations allowing either antiarrhythmic drug during resuscitation.

来源:Chest,查看原文。版权归原作者所有。

参考来源

  1. Niu X, Jiang T, Zheng W, et al. Comparative Effectiveness of Lidocaine and Amiodarone for Refractory Ventricular Fibrillation/Pulseless Ventricular Tachycardia in Adult In-Hospital Cardiac Arrest: Insights From a Nationwide Multicenter Chinese Registry. Chest. 2026. PMID: 42767592. doi:10.1016/j.chest.2026.08.052

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。